nuvigtx-com/
17 pages · Updated July 26, 2026
Pages
- Privacy Policy | Nuvig Therapeutics
- nuvig-keystone-abstract-may-2024-pdf.html
- Nuvig Therapeutics | Our Science
- Terms of Use | Nuvig Therapeutics
- Nuvig Therapeutics | Pipeline
- Team | Nuvig Therapeutics
- Nuvig Therapeutics | Cookie Policy
- Careers to Transform Medicine | Nuvig Therapeutics
- Nuvig Contact | Novel Therapies for Chronic Autoimmune Diseases
- Nuvig News | Novel Therapies for Chronic Autoimmune Diseases
- Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer | Nuvig Therapeutics
- Nuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair | Nuvig Therapeutics
- Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data | Nuvig Therapeutics
- Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator | Nuvig Therapeutics
- Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089 | Nuvig Therapeutics
- Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer | Nuvig Therapeutics
- Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases | Nuvig Therapeutics